A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OPERA® FOR REDUCING TREATMENT DISCONTINUATION IN RESECTED COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY

Data: 01 Aprile 2017

Autore: Prof. S.Cascinu - Division of Oncology, University Hospital of Modena

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OPERA® FOR REDUCING TREATMENT DISCONTINUATION IN RESECTED COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY

Sottoposto al comitato etico

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OPERA® FOR REDUCING TREATMENT DISCONTINUATION IN RESECTED COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY

Study Objective(s):

Primary: To evaluate the efficacy of Opera® in preventing oxaliplatin dose reductions, cycles delays and patient withdraw in patients receiving oxaliplatin-containing adjuvant chemotherapy for resected colorectal cancer

Secondary: To evaluate the impact of Opera® on treatment efficacy 

01/04/2017 Protocollo STOP (everolimus-induced STOmatitis Prevention trial) -ON PRESS

di GION - Coodinatore dr. C. PORTA- Policlinico S. Matteo Pavia


Prodotti in farmacia

disponibili in farmacia
e parafarmacia